Tezspire Crushes Eosinophilic Esophagitis Trial in Major Victory

Amgen and AstraZeneca's Tezspire has scored a major victory in treating eosinophilic esophagitis, a chronic inflammatory condition that affects millions worldwide. The Phase III CROSSING trial enrolled 368 patients aged 12-80 years with symptomatic, histologically active EoE who were uncontrolled on maintenance therapy.

Patients were randomized to receive either low-dose or high-dose Tezspire, administered subcutaneously every four weeks, or a placebo. The co-primary endpoints at week 24 were histologic remission and mean change from baseline in the Dysphagia Symptom Questionnaire (DSQ) score. Both were met with statistically significant and clinically meaningful improvements versus placebo.

The safety profile of Tezspire was consistent with its approved indications, including severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The companies will submit the CROSSING data to regulatory authorities as quickly as possible.